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Vascular diseases include cardiovascular and peripheral vas-
cular diseases. For decades, cardiovascular diseases (CVD)
stay the number one mortality worldwide. In more details,
coronary heart disease or stroke alone caused around 1 of
every 6 deaths or 1 of every 19 deaths in the United States
in 2010, respectively [1]. The total direct and indirect cost of
CVD remains higher than any other diagnostic groups such
as cancer [1].
In contrast to CVD, peripheral vascular diseases suffer
lack of attention because most of the affected individuals are
asymptomatic.The prevalence of peripheral vascular diseases
is increasing which reduces the life quality and exposes the
risk of infection and thrombosis. Atherosclerosis serves as
the common pathogenesis of peripheral arterial disease and
coronary heart disease. Therefore, both types of diseases
share the same risk factors. For instance, a recent study
demonstrated reduced number of endothelial progenitor cells
in patients with CVD [2] and PAD [3].
Patients with vascular diseases are always featured as
raised blood pressure, obesity, diabetes, and dyslipidemia,
all of which constitute metabolic syndrome. From 2003-
2004 to 2011-2012, the prevalence of the metabolic syndrome
increased from 32.9% to 34.7% [4]. When compared to
healthy controls, cardiovascular mortality was 1.6-fold higher
in the subjects who had metabolic syndrome [5]. Up to date,
in vitro and animal studies have consistently illustrated that
metabolic disorders disrupt endothelium integrity, promote
inflammation and thrombosis, and thus accelerate the pro-
gression of vascular diseases [6–8].
Physically, damaged endothelial cells and cardiomyocytes
could be replaced by proliferation of neighboring resident
cells or stem/progenitor-mediated repair. However, in the
occurrence of vascular diseases and metabolic disorders, the
balance between cell damage and repair is twisted. Because
of its fundamental potential in self-renewal and multilin-
eage differentiation capacity, stem cell-related therapy has
developed and reformed the manner of remodeling human
degenerative diseases, which could be applied for diagnosis,
drug screening, and the likelihood for therapy. Among all
types of stem cells, mesenchymal stem cells MSCs are one
of the most promising ones for translational application. A
number of preclinical studies have employed MSC for the
treatment of cardiomyopathy, vascular stenosis, and corneal
disease [9].
In the special issue, studies from clinical and basic re-
search were selected that presented the current status of
vascular diseases and metabolic disorders. Clinical results
brought updated findings on Acute Coronary Syndrome
as well as peripheral artery disease, aortic aneurysms, and
diabetic microvascular complications. We were informed
about the effect of stem cell therapy in the treatment of
vascular diseases. The report of “type 2 diabetes mellitus sus-
ceptible to pulmonary tuberculosis” enriched our knowledge
on diabetes. From the basic research aspect, we got to know
more about the physiology of endothelial cells and brown
adipocytes.
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